Zhitong Finance App News, Yahong Pharmaceutical (688176.SH) announced that the first phase I clinical trial of the APL-2401 developed by the company in advanced solid tumor patients driven by FGFR2/3 has completed the enrollment of the first test subjects.

Zhitongcaijing · 4d ago
Zhitong Finance App News, Yahong Pharmaceutical (688176.SH) announced that the first phase I clinical trial of the APL-2401 developed by the company in advanced solid tumor patients driven by FGFR2/3 has completed the enrollment of the first test subjects.